vs
GENMAB A/S（GMAB）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是美泰的1.1倍（$925.0M vs $862.2M），GENMAB A/S净利率更高（36.3% vs 7.1%，领先29.2%），GENMAB A/S同比增速更快（18.7% vs 4.3%），GENMAB A/S自由现金流更多（$327.0M vs $-88.1M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
GMAB vs MAT — 直观对比
营收规模更大
GMAB
是对方的1.1倍
$862.2M
营收增速更快
GMAB
高出14.4%
4.3%
净利率更高
GMAB
高出29.2%
7.1%
自由现金流更多
GMAB
多$415.1M
$-88.1M
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $862.2M |
| 净利润 | $336.0M | $61.0M |
| 毛利率 | 93.8% | 44.9% |
| 营业利润率 | 38.9% | — |
| 净利率 | 36.3% | 7.1% |
| 营收同比 | 18.7% | 4.3% |
| 净利润同比 | 65.5% | 251.4% |
| 每股收益（稀释后） | $5.42 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABMAT
| Q1 26 | — | $862.2M | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $925.0M | $1.0B | ||
| Q1 25 | — | $826.6M | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $779.0M | $1.1B |
净利润GMABMAT
| Q1 26 | — | $61.0M | ||
| Q4 25 | — | $106.2M | ||
| Q3 25 | — | $278.4M | ||
| Q2 25 | $336.0M | $53.4M | ||
| Q1 25 | — | $-40.3M | ||
| Q4 24 | — | $140.9M | ||
| Q3 24 | — | $372.4M | ||
| Q2 24 | $203.0M | $56.9M |
毛利率GMABMAT
| Q1 26 | — | 44.9% | ||
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 50.0% | ||
| Q2 25 | 93.8% | 50.9% | ||
| Q1 25 | — | 49.4% | ||
| Q4 24 | — | 50.7% | ||
| Q3 24 | — | 53.1% | ||
| Q2 24 | 96.4% | 49.2% |
营业利润率GMABMAT
| Q1 26 | — | — | ||
| Q4 25 | — | 8.0% | ||
| Q3 25 | — | 21.9% | ||
| Q2 25 | 38.9% | 7.7% | ||
| Q1 25 | — | -6.4% | ||
| Q4 24 | — | 9.6% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | 30.3% | 7.7% |
净利率GMABMAT
| Q1 26 | — | 7.1% | ||
| Q4 25 | — | 6.0% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | 36.3% | 5.2% | ||
| Q1 25 | — | -4.9% | ||
| Q4 24 | — | 8.6% | ||
| Q3 24 | — | 20.2% | ||
| Q2 24 | 26.1% | 5.3% |
每股收益（稀释后）GMABMAT
| Q1 26 | — | $0.20 | ||
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $0.88 | ||
| Q2 25 | $5.42 | $0.16 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $1.09 | ||
| Q2 24 | $3.13 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $866.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $5.3B | $2.1B |
| 总资产 | $6.5B | $6.3B |
| 负债/权益比越低杠杆越低 | — | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资GMABMAT
| Q1 26 | — | $866.0M | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $691.9M | ||
| Q2 25 | $1.3B | $870.5M | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $723.5M | ||
| Q2 24 | $622.0M | $722.4M |
总债务GMABMAT
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
股东权益GMABMAT
| Q1 26 | — | $2.1B | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $5.3B | $2.2B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $4.4B | $2.0B |
总资产GMABMAT
| Q1 26 | — | $6.3B | ||
| Q4 25 | — | $6.6B | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | $6.5B | $6.2B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | — | $6.5B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | $5.6B | $5.9B |
负债/权益比GMABMAT
| Q1 26 | — | 1.11× | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.03× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | — |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $-88.1M |
| 自由现金流率自由现金流/营收 | 35.4% | -10.2% |
| 资本支出强度资本支出/营收 | 2.4% | 7.6% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABMAT
| Q1 26 | — | — | ||
| Q4 25 | — | $796.6M | ||
| Q3 25 | — | $72.0M | ||
| Q2 25 | $349.0M | $-300.1M | ||
| Q1 25 | — | $24.8M | ||
| Q4 24 | — | $862.1M | ||
| Q3 24 | — | $155.8M | ||
| Q2 24 | $438.0M | $-252.9M |
自由现金流GMABMAT
| Q1 26 | — | $-88.1M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $327.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $430.0M | — |
自由现金流率GMABMAT
| Q1 26 | — | -10.2% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.2% | — |
资本支出强度GMABMAT
| Q1 26 | — | 7.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.0% | — |
现金转化率GMABMAT
| Q1 26 | — | — | ||
| Q4 25 | — | 7.50× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | 1.04× | -5.62× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.12× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | 2.16× | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
MAT
暂无分部数据
